Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1937-1943

  Wong, N A C S ^a   Brett, L ^a   Stewart, M ^b   Leitch, A ^c   Longley, D B ^d   Dunlop, M G ^c   Johnston, P G ^d   Lessells, A M ^a   Jodrell, D I ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

5 fluorouracil; Colorectal carcinoma; Immunohistochemistry; Metastases; p53 protein; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; KI 67 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TS106; MUCIN; PROTEIN P53; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

EID: 0035555656     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2175     Document Type: Article

References (42)

1. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
2. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil
3. Significance of angiogenesis in tumour progression and metastasis
4. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer
5. Mismatch repair proficiency and in vitro response to 5-fluorouracil
6. Identification of in vivo target RNA sequences bound by thymidylate synthase
7. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
8. Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice
9. Immunohistochemical determination of thymidylate synthase in colorectal cancer- methodogical studies
10. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer
11. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy
12. The development and optimization of a quantitative RT-PCR technique from formalin-fixed and paraffin-embedded (FFPE) tissues, using the thymidylate synthase gene as a target
13. Assessment of response to therapy in advanced breast cancer
14. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
15. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
16. 5-Fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer
17. Production and characterisation of monoclonal antibodies that localise human thymidylate synthase in the cytoplasm of human cells and tissue
18. The role of thymidylate synthase expression in prognosis and outcome in adjuvant chemotherapy in patients with rectal cancer
19. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
20. Determination of relative thymidylate synthase (TS) gene expression in tumour specimens and normal colon mucosa- relation to TS protein levels
21. Inhibition of mouse thymidylate synthase promotor activity by the wild-type p53 tumor suppressor protein
22. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
23. p53 and thymidylate synthase expression in untreated stage II colon cancer: Association with recurrence, survival and site
24. p53 point mutation and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
25. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antibodies
26. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
27. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
28. Thymidylate synthase and drug resistance
29. Thymidylate synthase is localized to the nuclear periphery in the yeast Saccharomyces cerevisiae
30. Prognosis and prediction of response in breast cancer: The current role of the main biological markers
31. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer
32. Role of substrate depletion in the inhibition of thymidylate biosynthesis by the dihydrofolate reductase inhibitor trimetrexate in cultured hepatoma cells
33. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
34. Intracellular location of thymidylate synthase and its state of phosphorylation
35. The role of thymidylate synthase levels in the prognosis of the treatment of patients with colorectal cancer
36. Immunohistochemical investigation of thymidylate synthase in cervical cancer
37. 5-Fluorouracil: A pharmacological paradigm in the use of cytotoxics
38. DNA mismatch repair and colorectal cancer
39. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
40. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance
41. The utility of the proliferative index in pretreatment biopsy specimens of esophageal squamous cell carcinoma